Technology with professional oversight.
AegisRX supports the preparation and organisation of medication reviews. It brings medication information, safety checks and points for discussion into a workspace where a pharmacist can assess the evidence, edit findings and sign the output before release.
AegisRX, within Artie Health.
GP practices, pharmacy teams, NHS organisations and private healthcare providers assessing medication-review technology.
Preparation that supports the reviewer
Medication reviews involve information from several sources and questions that need professional consideration. AegisRX organises the available information and highlights areas for review, including medicine combinations and monitoring gaps. This gives the pharmacist material to assess in context. The relevance of a finding still depends on the individual circumstances and the quality of the information available.
Oversight at the point of release
Deterministic safety rules operate independently of the AI components. A named pharmacist reviews the findings, makes any necessary edits and signs each released output. The software does not automatically change medicines or make prescribing decisions. Those responsibilities remain with the relevant healthcare professional, using their judgement and the information needed for the patient’s care.
A process an organisation can examine
AegisRX records sources, decisions, actions and sign-offs so the review process can be traced. Organisations considering the software can request its clinical safety, data protection and deployment documentation for their own assessment. The published evidence pages distinguish the guidance informing the approach from evaluation of the product itself, keeping those different forms of evidence clear.
A little more
about AegisRX.
Does AegisRX replace the pharmacist’s review?
No. It supports preparation and review, with a named pharmacist checking, editing and signing released outputs. Any change to medicines remains a decision for the responsible prescriber. Automated findings are material for assessment rather than a completed clinical decision.
How can a healthcare organisation explore it?
Use the AegisRX website to request a demonstration and discuss the proposed setting. The team can share information about the software, its governance and deployment arrangements so your organisation can assess suitability and the scope of any proposed use.